Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 3/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | CPA3 | P15088 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517307 | 1.00 | CPA1 (0.47) | CPA1CPB2CPB1CPA3FOLH1 | |
| SCHEMBL4510891 | 0.85 | POLB (0.37) | CPA1CPB2CPB1CPA3FOLH1 | |
| SCHEMBL4510897 | 0.85 | POLB (0.37) | CPA1CPB2CPB1CPA3FOLH1 | |
| SCHEMBL4461700 | 0.81 | CPA1 (0.45) | CPA1CPB2CPB1CPA3FOLH1 | |
| SCHEMBL4478582 | 0.81 | CPA1 (0.45) | CPA1CPB2CPB1CPA3FOLH1 | |
| SCHEMBL3520174 | 0.80 | CPA1 (0.44) | CPA1CPB2CPB1CPA3FOLH1 | |
| SCHEMBL3520168 | 0.80 | CPA1 (0.44) | CPA1CPB2CPB1CPA3FOLH1 | |
| SCHEMBL3960052 | 0.79 | CPA1 (0.56) | CPA1CPB2CPB1CPA3FOLH1 | |
| SCHEMBL3960051 | 0.79 | CPA1 (0.56) | CPA1CPB2CPB1CPA3FOLH1 | |
| SCHEMBL3960054 | 0.79 | CPA1 (0.56) | CPA1CPB2CPB1CPA3FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7696209-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20090186881-A1 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186881-A1 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CPA1 1052/4885CPB2 3140/4885CPB1 3147/4885 |
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CPA1 1041/4885CPB2 3077/4885CPB1 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.